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Precis: 
Childhood cancer survivors possess a higher risk for cardiovascular disease (CVD) 
compared to age-matched peers. Retinal vessel analysis could be used to identify 




Microvascular endothelial dysfunction is central to the pathogenesis of CVD. The eye 
offers direct access for endothelial health assessment via the retinal microvasculature. 
Using rigorous software analysis, we investigated whether image-based retinal vessel 
analysis is a feasible method of assessing endothelial health in childhood cancer survivors 
(CCS). 
Methods 
Cardiovascular risk factors (CRF) were estimated using the 30-year Framingham Heart 
Study Risk Score in 78 survivors of childhood leukaemia (median age: 26, IQR 23-29; 
median years from diagnosis: 19, IQR 14-22) and 78 healthy controls (median age: 24, 
IQR 23-27). Radial arterial stiffness was measured using pulse wave analyser, while 
endothelial activation markers were measured by soluble intercellular adhesion molecule 
1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1). Retinal fundus 
images were analysed on Vascular Assessment and Measurement Platform for Images of 
the REtina (VAMPIRE) software for central retinal artery/vein equivalents (CRAE/CRVE) 
and arteriolar-venular ratio (AVR).  
Results 
CCS had higher CRF (p<0.0001), arterial stiffness (p<0.001) and sVCAM-1 (p=0.002) 
compared to controls. Survivors also had significantly higher CRVE (p=0.022) whilst AVR 
was significantly lower (p=0.042) than in controls, compatible with endothelial dysfunction. 
Survivors with intermediate CRF exhibited lower CRAE compared to survivors with low 
CRF (p=0.033). In a regression model, CRAE of the survivors was negatively associated 
with CRF (ß=-0.381, p=0.037) along with covariates (age, gender and smoking status). 
Conclusions 
CCS had evidence of endothelial dysfunction and increased risk of cardiovascular disease 
compared to controls.  Retinal vessel analysis is comparable to pulse wave analysis and 
may be utilized as a robust screening tool for detecting CCS at risk of developing CVD.  
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Late-effects of therapy with significant health impact especially cardiovascular disease 
(CVD) are a major concern in childhood cancer survivors (CCS).1 Cohort studies from 
the United States as well as Europe have shown that young adult survivors of 
childhood cancer have an up to 7-fold higher risk of death from cardiac causes 
compared to age‐, and sex‐matched members of the general population.2-4 Impaired 
endothelial function is postulated as the initial step in the pathogenesis of 
atherosclerosis.5 Various manifestations of cardiovascular disease such as 
cardiomyopathy and vasculopathy are believed to be the downstream complications 
driven by atherosclerosis.6-8  The advancement of pathophysiological insights in CVD 
has allowed sensitive detection of biomarkers and non-invasive in vivo detection of a 
pre-atherosclerotic signature through evaluation of endothelial dysfunction.9-11  
 
CCS, especially those with prior exposure to anthracyclines, exhibit preclinical 
vasculopathy, marked by increased arterial stiffness and endothelial dysfunction.12 
Two studies assessing vascular endothelial function by brachial artery reactivity, also 
demonstrated that CCS have impaired vascular endothelial function compared to their 
cancer-free counterparts.13,14 
 
There is increasing appreciation that coronary microvascular dysfunction plays a 
crucial role in coronary heart disease15 although difficulties in studying the coronary 
microcirculation directly has impeded our understanding regarding this connection. 
The eye offers direct access to the retinal microvasculature, thus through high-quality 
imaging and assistance of reliable, validated computer software, the retinal 
vasculature may be non-invasively evaluated.16 Using the VAMPIRE software, as with 
other similar analysis platforms such as IVAN, SVA-T and SIVA, retinal vessels can 
be analysed as biomarkers of systemic conditions such diabetes17,18, hypertension19, 
cardiovascular disease20,21 as well as neurodegenerative conditions such as 
Alzheimer’s disease.22 Multiple studies have shown that changes in retinal vessel 
diameter are associated with risk of cardiovascular disease (CVD)23-25 and stroke 
mortality26,27, independent of traditional risk factors. 
In this study, we assessed vascular endothelial health in a cohort of CCS and 
investigated the association of these changes with cardiovascular risk factors, with the 




Young adult survivors of childhood leukemia were recruited into this study. The 
inclusion criteria were: (i) individuals aged 18–35 years, (ii) 5 or more years since 
completion of leukemia treatment, (iii) no history of hematopoietic stem cell 
transplantation, (iv) no acute illness or pregnancy at the point of recruitment, and (v) 
did not receive a vaccination in the 6 months prior to recruitment. Age-matched 
volunteer controls were recruited amongst subjects’ siblings, partners and hospital 
staff. All participants gave written consent to enrol in the study.  The study protocol 
was approved by the hospital research ethics board (MREC 2014/1093.65) and 
followed the principles of the Helsinki Declaration. A standardized questionnaire was 
used to collect demographic details and smoking history. Physical examination as well 
as biochemical screening were performed on all participants while a detailed history 
of cancer treatment was obtained from medical records by two independent 
researchers to ensure accuracy. 
 
Biochemical parameters 
Blood glucose, serum lipid profile and high-sensitivity C-reactive protein (hsCRP) 
levels were measured by the hospital’s diagnostic laboratory within 4 hours of 
venepuncture.  
 
Risk factors for cardiovascular disease 
Risk for developing cardiovascular disease within 30 years was estimated using the 
Framingham Heart Study Risk Score.28 Using this assessment tool, the  
Cardiovascular Risk Factor (CRF) score was calculated using the following 
parameters: gender, age, systolic blood pressure, usage of antihypertensive agents, 
smoking status, presence of diabetes mellitus, serum total cholesterol and high-
density lipoprotein (HDL).28 ‘Full’ CRF is defined as risk of getting coronary death, 
myocardial infarction, coronary insufficiency, angina, transient ischemic attack, 
periphery artery disease, heart failure and strokes including ischemic and 
haemorrhagic stroke.28  
 
Pulse wave analysis 
Arterial stiffness was inferred through measuring the augmentation index (AIx) of the 
brachial artery using a cuff based pulse wave analyser, SphygmoCor XCEL PWA 
(AtCor Medical, Sydney, Australia). AIx is the difference between the early systolic 
pressure and the late systolic peak of the central aortic waveform, expressed as a 
percentage of pulse pressure. Measurements were taken from a partially inflated 
brachial cuff and the brachial artery waveforms were calibrated using cuff-measured 
systolic and diastolic pressures. The arterial pulse waves were processed by the 
system software using a validated transfer factor as previously described.29 
 
Retinal vessel caliber analysis 
Each subject underwent eye fundus screening and retinal digital photography at the 
Ophthalmology out-patient clinic in University of Malaya Medical Centre. Prior to 
photography, 0.5% proparacaine hydrochloride plus 1% tropicamide eye drops were 
instilled into each eye for pupillary dilation. Colour retinal digital images (35 degrees 
field of view) were obtained using a TopCon digital fundus camera (TRC-50DX). For 
standardisation, only images from the left eye were analysed in this study. 
Retinal vessel calibre parameters were measured using the VAMPIRE (Vessel 
Assessment and Measurement Platform for Images of the REtina) software suite 
(version 3.0; Universities of Edinburgh and Dundee, UK).16,30,31 Images of insufficient 
quality or low contrast were excluded from the analysis by the software operators. The 
assessors were blinded to the subjects’ clinical information.  
 
Following convention, we used optic disc (OD) centered images for analysis.32,33  The 
software first automatically detects the centre of the OD and of the macula using 
validated algorithms, reported elsewhere.30,31 This establishes a reference frame 
delineating the standard zones A, B and C, i.e., circular sectors (annuli) concentric 
with the OD, delimited by circles of radii 0.5 and 1 OD diameters (A), 1 and 1.5 (B), 
1.5 and 2 (C) . Next, vessels were automatically segmented and classified as arteries 
or veins. To maximize accuracy, a software operator performed manual corrections to 
rectify possible software errors, e.g. i.e. OD and macula location, vessel labels (A/V) 
or and vessel selected for CRAE and / CRVE calculation. CRAE and CRVE were 
calculated according to the Parr and Hubbard formula34 and allied protocols, selecting 
6 main arteries and veins in Zone B wherever possible. Local vessel widths were 
estimated using a validated algorithm35 as the mean of 7 measures taken every 3 
pixels along the zone-B vessel segment.  Width estimates with high standard deviation 
(those in the extreme 10 percentiles) were discarded as unreliable.  
Endothelial activation markers 
Endothelial activation markers, soluble intercellular adhesion molecule 1 (sICAM-1) 
and soluble vascular cell adhesion molecule 1 (sVCAM-1) were measured by BD 
Cytometric Bead Array (CBA) immunoassay (BD Biosciences, Breda, The 
Netherlands). Individual blood plasma concentration (1:256) was derived from 
standard curves generated using purified ICAM-1 and VCAM-1 provided by the 
manufacturer. Samples were then incubated with the beads for each marker. Analysis 
was performed by flow cytometer using FCAP Array version 1 software. 
 
Statistical analysis 
Comparison between groups for continuous variables was made using the Mann-
Whitney U test. Analysis of covariance (ANCOVA) and partial correlation were 
performed to investigate the relationship of endothelial dysfunction markers (AIx, 
sICAM-1 and sVCAM-1) and retinal vessel parameters (CRAE, CRVE and AVR) with 
Framingham’s 30-year full CVD risk, after adjusting for age. Correlation among 
continuous parameters within CCS was calculated using Spearman’s correlation.  
Multiple linear regression was used to study the relationship of endothelial dysfunction 
and retinal vessel parameters with Framingham’s 30-year full CVD risk. All analyses 
were performed using the IBM SPSS Statistics version 20 and figures were generated 




Seventy-eight asymptomatic young adult survivors of childhood acute lymphoblastic 
leukemia (ALL) were recruited. Clinical characteristics of subjects, including treatment 
history for the survivors, are shown in Table 1. The median age at recruitment for 
survivors and controls are 26 and 24 years old respectively. As ALL treatment 
protocols were risk-stratified according to individual disease biology, subjects did not 
all receive uniform therapy. Of note, the number of subjects who received 
anthracyclines, alkylating agents and radiotherapy were 72%, 73% and 49% 
respectively.     
 
Cardiovascular disease risk factor (CRF) 
CRF of the subjects based on clinical parameters is shown in Figure 1. Overall, 
survivors had higher blood glucose (p=0.004), total serum cholesterol (p=0.011), 
triglyceride (p<0.001), LDL (p=0.005) and hsCRP (p=0.007) when compared to 
controls. Similarly, systolic (p<0.001) and diastolic (p=0.001) blood pressure of 
survivors were significantly elevated compared to controls. Framingham Heart Study 
Risk Score was used to predict 30-year CRF in both leukemia survivors and controls 
(Fig. 2). Survivors had a higher 30-year Framingham Heart Study Risk Score for full 
CVD compared to controls (p<0.0001). 
 
Arterial stiffness and markers of endothelial activation  
Arterial stiffness of survivors as measured through augmentation index (AIx) was 
significantly higher in survivors than controls (p<0.001, Figure 3A). Survivors had 
significantly increased levels of the endothelial activation marker, sVCAM-1 (p=0.002), 
but not sICAM-1 (p=0.090) compared to controls (Fig. 3B-C). 
 
Retinal vessel caliber analysis 
Retinal vessel caliber analysis showed that central retinal vein equivalent (CRVE) was 
significantly higher in survivors (p=0.022, Fig. 4B), while central retinal artery 
equivalent (CRAE) was comparable in survivors compared to controls (p=0.511, Fig. 
4A). Consequently, the arterio-venous ratio (AVR=CRAE/CRVE) of survivors was 
significantly lower than in controls (p=0.042, Fig. 4C).  
 
Association of endothelial dysfunction markers and retinal vessel caliber 
analysis with cardiovascular risk factors 
The association of arterial stiffness, endothelial activation markers and retinal vessel 
caliber diameters with Framingham’s 30-year full CVD risk score were then analyzed 
among survivors. Survivors with intermediate CRF showed lower CRAE compared to 
survivors with low CRF (p=0.033, Fig. 5 A) calculated using ANCOVA adjusted for 
age. Parameters of CRVE, AVR, augmentation index, sVCAM-1 and sICAM-1 were 
all similar between survivors with intermediate and low CRF (Fig. 5B-F). In 
Spearman’s correlation, AVR is inversely correlated with sVCAM-1 (r=-0.464, 
p=0.026). In multiple linear regression analysis, CRAE was independently associated 
with Framingham’s 30-year full CVD risk score, along with covariates of age, smoking 
status and gender (Table 2). 
DISCUSSION 
Exposure to cytotoxic agents and radiation have rendered childhood cancer survivors 
at an increased risk of developing cardiovascular disease, metabolic syndrome, 
diabetes, hypertension and other conditions as a result of long-term vascular 
complications.36-39 In this study, we have shown that clinical biomarkers of CVD are 
significantly elevated in young adult survivors of childhood leukemia. 
Previously, we reported that childhood leukemia survivors had a biological signature 
of inflammation. In particular, survivors had significantly elevated levels of serum 
hsCRP.40 CRP has been shown to be a sensitive biomarker associated with metabolic 
syndrome, cardiovascular disease and microvascular complications in the general 
population.41-43 Additionally, CRP is also associated with albuminuria in individuals 
with diabetes, which is a known marker of diabetic nephropathy.44-46 
We hypothesise that inflammation may play an important role in late effects observed 
among CCS, although the exact pathophysiological mechanisms remain to be 
elucidated. Therapy-induced damage to normal cells may be associated with systemic 
chronic inflammation, leading to premature aging and late effects in CCS. Individuals 
exposed to cancer therapy are at risk of cardiovascular damage.47 In a Swedish and 
Danish cohort of breast cancer survivors, the incidence of a major coronary event 
increased linearly with the mean dose of thoracic radiotherapy (RT) by 7.4% per gray 
(Gy).48 It is intriguing that CCS whose exposure to radiotherapy is restricted to the 
cranium still exhibit higher cardiovascular disease risk compared to the general 
population.49,50 This observation is likely secondary to the endocrinopathies arising 
from irradiation to the hypothalamic-pituitary system51, with consequences of 
hormonal imbalance and development of metabolic syndrome. 
Another important component of many childhood cancer treatment protocols are the 
anthracyclines. In rat models, anthracyclines especially doxorubicin have been shown 
to cause structural and functional damage to the heart.52,53 In humans, anthracyclines 
have been associated with various coronary pathology such as arrhythmia, pericarditis 
and myocarditis.2,13,54-56 Recent studies have also shown that anthracyclines have the 
propensity to induce toxicity in the vascular endothelium12-14,54, the antecedent event 
in the etiology of atherosclerosis.  
In our study, we have shown that CCS have endothelial dysfunction, concurring with 
results published by other groups.57,58 Endothelial dysfunction is a crucial factor in 
atherosclerosis-related diseases.10 In our study, we have shown that sVCAM-1 is 
elevated in CCS compared to controls. The accumulation of inflammatory cells during 
plaque formation activate endothelial cells that express adhesion molecules such as 
VCAM-1.59 Endothelial cell activation is typically induced by proinflammatory cytokines 
particularly Interleukin-6 and Tumour Necrosis Factor-alpha.60 This state of endothelial 
activation and increased inflammation may promote plaques to be more vulnerable to 
rupture and consequently, to myocardial infarction or acute coronary syndromes.10  
Retinal vessel analysises supports the findings of increased CVD risk among 
childhood cancer survivors. We found a narrower retinal arteriolar diameter in our 
leukemia survivor group, but a significantly lower AVR - both parameters have been 
implicated in increased cardiovascular morbidity and mortality.61,62 In a large 
population-based study analysing 1,900 participants in Rotterdam, each SD decrease 
in AVR significantly raised the risk of hypertension by 24%.61 Additionally, we also 
observed an inverse correlation between AVR and sVCAM-1, a marker which has 
been shown to be elevated in individuals with arterial stiffness.63,64  
When analysed independently however, we found a significant inverse relationship 
between CRAE and CVD risk score among survivors. CRAE was also the sole marker 
which retained its significance in multiple linear regression analysis. Compared to 
AVR, generalized retinal arteriolar narrowing is more strongly associated with the risk 
of hypertension.61 In a recent Dutch study  among overweight and obese children 
(n=226, median age=13 years), CRAE has been shown to be correlated with 
cardiovascular risk factors such as plasma glucose and LDL, indicating that retinal 
vessel analysis parameters may be suitable even in children.65 Furthermore, we were 
able to detect significantly higher CRVE in the survivor group in our cohort. Increased 
retinal venular diameter has been associated with the risk of stroke and cerebral 
infarction66, heart diseases67  and overall increased cardiovascular deaths.68 Taken 
together, retinal vessel analysis gives a real-time reflection of systemic microvascular 
health, and may be used as a predictive tool to identify CCS at risk of cardiovascular 
disease. Its relative simplicity and affordable infrastructural requirements make retinal 
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Table 1. Demographic of survivors and controls 
 Group 
 Survivors Controls 
Number in each group 78 78 
Sex, n (%)   
Male 39 (50%) 31 (44%) 
Female 39 (50%) 40 (56%) 
Age at recruitment, years 26 (23-29) 24 (23-27) 
Age at diagnosis, years 5 (4-9) NA 
*BMI, kg/m2 23.7 (20.7-28.7) 22.1 (20.4-24.9) 
Diagnosis, n (%)   
ALL 73 (94%) NA 
AML 5 (6%) NA 
Duration since chemotherapy, years 19 (14-22) NA 
Chemotherapy received   
Antracyclines, n (%) 56 (72%) NA 
Antracycline cumulative dosage, mg/m2 240 (0-240) NA 
Alkylating agents, n (%) 57 (73%) NA 
Alkylating agent cumulative dosage, mg/m2 2000 (0-3000) NA 
Radiotherapy received, n (%) 38 (49%) NA 
Radiotherapy dosage, Gy 18 (0-18) NA 
*Smoking status, n (%)   
Smoker 12 (15%) 2 (3%) 
Non-smoker 46 (59%) 66 (93%) 
Not available 20 (26%) 1 (1%) 
     Data shown are median (interquartile range, IQR) or n (%). 
     NA indicates not applicable.   
     *Variables that are significantly different (p<0.05 on Mann Whitney or Chi-square tests) in 









Table 2. Association between retinal vessel diameters, endothelial dysfunction markers and 
covariates of age, gender and smoking status with Framingham’s 30-year full CVD risk score 
calculated using multiple linear regression 
 
 Coefficient, β 95% CI P-value 
AIx, % -0.015 -0.129 to 0.098 0.780 
sVCAM-1, pg/mL 8.181x10-6 -3.689x10-5 to -5.325x10-5 0.703 
sICAM-1, pg/mL 1.733x10-5 -5.367x10-6 to -4.003x10-5 0.124 
CRAE, px -0.381 -0.735 to -0.026 0.037* 
CRVE, px 0.234 -0.151 to 0.618 0.213 
Age, year 0.830 0.496 to 1.164 <0.001* 
Smoking status, smoker 6.444 2.704 to 10.184 0.002* 
Gender, male 4.529 1.166 to 7.891 0.012* 
     Variable were initially checked for collinearity using linear regression and variable with variance 
inflation factor (VIF) of >10 (AVR) was excluded. 
























Figure 1. Clinical cardiovascular risk factor for leukemia survivors and controls. 
(A) Glucose, (B) total cholesterol, (C) systolic blood pressure, (D) diastolic blood 
pressure, (E) triglyceride, (F) high-density lipoprotein (HDL), (G) low-density 
lipoprotein (LDL), and (H) high-sensitivity C-reactive protein (hsCRP). Survivors had 
higher blood glucose, total serum cholesterol, blood pressure, LDL and hsCRP, and 
had lower HDL compared to controls. 
Figure 2: 30-year risk of full CVD for leukemia survivors and controls. 30-year 
Framingham Heart Study Risk Score for full CVD calculated using lipid profile. * 
denotes significant p-value calculated using Mann-Whitney U-test. Bars represent 
median and interquartile range. 
Figure 3. Arterial stiffness and endothelial activation markers for leukemia 
survivors and controls. Survivors had higher (A) augmentation index (AIx) and (B) 
soluble VCAM-1 (sVCAM-1) compared to controls. Level of (C) soluble ICAM-1 
(sICAM-1) between survivors and controls were similar. * denotes significant p-values 
calculated using Mann-Whitney U-test. Bars represent median and interquartile range. 
Figure 4. Retinal vessel caliber analysis of leukemia survivors and controls. (A) 
Central retinal artery equivalent (CRAE) (B) central retinal vein equivalent (CRVE) and 
(C) arterio-venous ratio (AVR). Survivors had higher CRVE and lower AVR compared 
to controls. * denotes significant p-values calculated using Mann-Whitney U-test. Bars 
represent median and interquartile range. 
 
Figure 5. Relationship of retinal vessel calibre analysis and endothelial 
dysfunction markers with Framingham’s 30-year risk for full CVD. An analysis of 
covariance (ANCOVA) was utilised to assess differences in retinal vessel calibre 
parameters: (A) CRAE, (B) CRVE and (C) AVR & endothelial dysfunction markers: 
(D) augmentation index, (E) sVCAM-1 and (F) sICAM-1; among survivors with low and 
intermediate risk for Framingham’s 30-year CVD risk score, adjusting for significant 
covariate (age). P<0.05 were considered statistically significant and are marked with 
an asterisk. Bars indicate medians and interquartile ranges. 
 
